Factor XI inhibition – are NOACs obsolete? Mechanistic and pharmacological insights

16 April 2023 (14:45 - 15:00)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Doctor Jeffrey Weitz

Thrombosis & Atherosclerosis Research Institute (TaARI), Hamilton (Canada)

4 More presentations in this session

Presentation thumbnail

This programme is supported by Bayer Pharma AG in the form of an educational grant. The scientific programme has not been influenced in any way by its sponsor

Presentation thumbnail

Non-vitamin K antagonist oral anticoagulants (NOACs) – Limitations and new opportunities

Professor J. Steffel (Zurich, CH)

Presentation thumbnail

Factor XI inhibition – the new paradigm for atrial fibrillation and stroke

Professor G. Lip (Liverpool, GB)

Presentation thumbnail

Factor XI inhibition – other indications: acute coronary syndrome, venous thromboembolism

Professor D. Capodanno (Catania, IT)

Access the full session

Session thumbnail

The new frontier in oral anticoagulation: Factor XIa inhibitors

The Event

Event poster

EHRA 2023

16 April 2023 14:45 CET

You may be interested in

Congress Presentation

Factor XI inhibition uncoupled: mechanistic insights and rationale

30 August 2024

Congress Session

From bench to bedside: how changes in the data landscape have shaped venous thromboembolism treatment as well as prevention of recurrence

26 August 2023

Congress Presentation

Discussant review - AXIOMATIC-SSP.

28 August 2022

Congress Presentation

Safety and efficacy of factor XI/XIa inhibitors compared to factor Xa inhibitors for stroke prophylaxis in atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials

30 August 2025

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources